Merck KGaA Q1 2022 earnings call: BAVENCIO global sales increased by 107.3% in Q1 2022 (YoY) and MAVENCLAD global sales increased by 28.7% in Q1 2022 (YoY)
Immuno-oncology Financial BAVENCIO global sales increased by 107.3% to $134M in Q1 2022 (as compared to $65M Q1 2021). BAVENCIO global sales increased by 5.5% in QoQ terms (as compared to $127M Q4 2021), particularly in EU and Japan ~5% QoQ growth driven by 1L mUC launch ramp-up in Europe, supported by the U.S. and […]